多西他赛表柔比星联合环磷酰胺方案在乳腺癌新辅助化疗中的应用

Clinical efficacy of TEC neoadjuvant chemotherapy in the treatment of breast cancer

目的探讨TEC(多西他赛、表柔比星、环磷酰胺)方案在乳腺癌新辅助化疗中的应用。方法选取2005年9月至2010年10月间进行新辅助化疗的乳腺癌患者187例,患者均采用TEC方案,分析该方案的疗效及不良反应。结果根据实体瘤疗效评价标准1.1(RECIST 1.1)进行评估,完全缓解(CR)23例,部分缓解(PR)113例,疾病稳定(SD)46例,疾病进展(PD)5例。新辅助化疗过程中,Ⅳ度骨髓抑制患者31例,且2例患者经过化疗药物剂量减量后持续出现Ⅳ度骨髓抑制,甚至并发严重感染,放弃新辅助化疗,进行手术治疗。结论 TEC方案对局部晚期乳腺癌行新辅助化疗,疗效确切,不良反应可以耐受。

Objective To investigate the clinical efficacy of docetaxel ＋ epirubicin ＋ cyclophosphamide（ TEC） neoadjuvant chemotherapy in the treatment of breast cancer. Methods From September2005 to October 2010 in Zhongshan Hospital Affiliated to Dalian University,187 patients with breast cancer who would accept neoadjuvant chemotherapy were enrolled in the study. All patients accepted TEC regimen.The clinical efficacy and adverse reactions were recorded. Results According to Response Evaluation Criteria in Solid Tumors（ RECIST） 1. 1,23 cases reached complete response（ CR）,113 cases partial response（ PR）,46 cases stable disease（ SD）,5 cases progressive disease（ PD）. During the neoadjuvant chemotherapy,31 patients had Ⅳ grade myelosuppression,2 of them had to give up the the neoadjuvant chemotherapy because of the serious infection due to the myelosuppression. Conclusion TEC neoadjuvant chemotherapy in the treatment of breast cancer could achieve good clinical efficacy and it is worthy of clinical promotion.